Pfizer remains materially undervalued, trading at a 9.1x forward earnings multiple and offering a compelling 6.7% dividend yield. LOE headwinds are moderating, with management now expecting $14–15 billion in losses, below prior peak estimates, easing long-term revenue concerns. Execution on recently launched and acquired products is strong, with 22% operational growth and a robust pipeline, particularly in oncology and weight loss.